Login to Your Account

Shares Rise 35 Percent

Savient Gout Drug Wins FDA OK; Firm for Sale

By Donna Young

Thursday, September 16, 2010
WASHINGTON – The FDA's approval late Tuesday of Savient Pharmaceuticals Inc.'s Krystexxa (pegloticase), a pegylated uric acid specific enzyme for chronic refractory gout, "symbolizes what a small biotech can do," said President Paul Hamelin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription